Antibody therapies for inflammatory and fibrotic diseases
Founders
Jonas Hallen(Norway · ♂)— A physician who met co-founders at Novartis and co-founded Arxx Therapeutics targeting inflammation and fibrosis; when Arxx merged with Oxitope Pharma in 2024 to form Calluna, he continued as co-founder and Chief Medical Officer.
Rizwan Hussain(Norway · ♂)— An entrepreneur and former Novartis colleague who co-founded Arxx Therapeutics in 2019 around DAMP-targeting immunology research, which became Calluna Pharma after the 2024 merger.
Joerg Klingelhoefer(Germany · ♂)— The scientist whose academic research on innate immunity formed the basis of Arxx Therapeutics, the Norwegian company that merged into Calluna Pharma.
Members see the full profile
Create a free EquityFlow account to see Calluna Pharma's 1 funding round, 3 investors, 12 similar companies.